The BenefitsPRO Broker Expo in Chicago commenced this year with intense focus on one of the most transformative, yet financially challenging, pharmaceutical developments: GLP-1 receptor agonist drugs. These medications, initially lauded for their efficacy in managing Type 2 diabetes, have garnered significant attention, and expenditure, for their profound impact on weight loss. The financial ramifications are staggering; according to a recent report in JAMA, spending on GLP-1s surged by a colossal 500% between 2018 and 2023, eclipsing $70 billion annually. This exponential growth, while promising for patient health outcomes, presents a formidable dilemma for employers already grappling with relentlessly escalating healthcare costs.
For employees primarily focused on the tangible benefits of these drugs – often measured by the numbers on a scale or improved health markers – the astronomical costs might seem distant. However, for employers, this financial burden translates into difficult decisions regarding benefits design, sustainability, and ultimately, the value proposition of such significant investments. The core question reverberating through corporate boardrooms and benefits strategy meetings is stark: Is this expenditure truly worth it, and how can its value be maximized?
The Unfolding Challenge: Rising Costs Meet Chronic Disease
The context for this urgent discussion is rooted in the broader landscape of American healthcare. Employers are the primary payers for health benefits for a substantial portion of the U.S. population, often bearing the brunt of rising medical and pharmaceutical expenses. According to industry analyses, employer-sponsored health insurance premiums have consistently risen year-over-year, with projections indicating continued upward trends. Chronic conditions, particularly Type 2 diabetes, represent a disproportionately large share of these costs due to ongoing medication, specialist visits, and potential complications like cardiovascular disease, kidney failure, and neuropathy. The Centers for Disease Control and Prevention (CDC) estimates that over 37 million Americans have diabetes, and another 96 million adults have prediabetes, underscoring the vast scope of the challenge.
Against this backdrop, the advent of GLP-1 drugs – including popular brands like Ozempic, Wegovy, Mounjaro, and Zepbound – has introduced a new layer of complexity. These medications work by mimicking a natural hormone, glucagon-like peptide-1, to stimulate insulin release, suppress glucagon, slow gastric emptying, and promote satiety, leading to improved glycemic control and significant weight reduction. While their clinical benefits are undeniable, particularly for individuals struggling with obesity and Type 2 diabetes, their high price point has made them a focal point of employer scrutiny.
Ben Conner, CEO of Conner Insurance, encapsulated the employer’s conundrum during his opening remarks at the BenefitsPRO Broker Expo. "Is it possible that we are spending millions of dollars on medications for our diabetes population and they are still sick?" he questioned, highlighting a pervasive concern that traditional approaches to managing chronic diseases, even with advanced pharmaceuticals, might not be yielding optimal health outcomes or financial returns. Conner initiated the session by presenting a compelling case study, demonstrating how his firm, in collaboration with a specialized wellness coach and a Pharmacy Benefit Manager (PBM) partner, engineered a data-driven strategy aimed at empowering employees to more effectively manage their diabetes.
Conner further elaborated on the gravity of the situation observed across his firm’s extensive client portfolio. "When we looked at our pharmacy situation across the book of business—how we’re spending money on specific conditions—diabetes was in and around 10 times more than any other group," he stated. This data point underscores the immense financial weight that diabetes places on employer health plans, making it an undeniable priority for strategic intervention.
A Proactive, Data-Driven Approach Yields Tangible Results
The innovative strategy championed by Conner Insurance and its partners delivered results that offer a beacon of hope for other employers. The initiative led to a remarkable million dollars in medical spend savings within the first year alone. Furthermore, there was a 19% decrease in per member per month (PMPM) costs for plan members diagnosed with diabetes. Perhaps most significantly, the health outcomes for high-risk employees were profoundly impacted: average A1C levels—a critical marker for long-term blood sugar control—among the highest-risk individuals plummeted from 11.3% to 8.5%. A truly transformative outcome was that 60% of the program participants demonstrated a positive trend towards diabetic remission, a state where individuals can maintain normal blood sugar levels without medication. These figures provide a powerful testament to the efficacy of a comprehensive, engagement-focused approach over merely covering high-cost medications.
GLP-1s: Beyond Weight Loss – Reclaiming Their Diabetic Heritage
A significant factor contributing to the current challenges around GLP-1s is the overwhelming public and media focus on their weight-loss properties. While revolutionary for chronic weight management, this emphasis has, to some extent, overshadowed their original and primary role in managing Type 2 diabetes. This shift in perception has implications for how these drugs are prescribed, covered, and utilized within employer benefits plans.
Betsy Bigler, President and COO of Northwind Health Company, shed light on this dynamic. "What we have seen is that manufacturers want employers to cover these medications, no questions asked," Bigler explained. "They did not want you to ask anything—not confirm a diabetes diagnosis or anything." This commercial strategy, while understandable from a market expansion perspective, has created a scenario where employers might be covering GLP-1s without sufficient clinical oversight or a clear understanding of the specific indication for which the drug is being prescribed.
This lack of precise diagnostic triage leaves many employers footing the bill for GLP-1s without a discernible return on investment that aligns with their benefits objectives. "We’re finding that it does take a triage period to find out why people are on GLP-1s," Bigler added. "You have GLP-1s for Type 2 diabetes, you have it for prediabetes and you have it for weight management." Distinguishing between these indications is crucial for employers to develop targeted coverage policies, ensure appropriate utilization, and measure the true impact on specific health populations. By adopting this nuanced perspective, benefits advisors and employers can collaborate to formulate strategic plans with measurable objectives, transforming drug spend from a mere line item into an integral piece of a broader, more effective healthcare puzzle.
Conner drew a powerful analogy to cancer treatment to explain the approach to diabetes management. "If you have diabetes, you don’t get cured, you go into remission," he stated. "If someone is on chemo and they go into remission, they’re going to go into a different treatment regimen. We approach diabetes the same way." This perspective emphasizes active management towards a state of remission, rather than simply perpetual medication, opening pathways for dynamic treatment plans that adapt to an individual’s improving health status.
Innovating Benefits Design: A Specialty PBM and Health Coaching Model
A cornerstone of the successful strategy implemented by Conner Insurance and the collaborating employer involved a radical departure from conventional PBM arrangements. Instead of including diabetic medications, including GLP-1s, within the employer’s standard PBM contract, they opted to establish a specialized PBM through Northwind Health Company. This specialty PBM was strategically paired with a mandatory health coaching program. This innovative structural change allowed for greater control, transparency, and a more integrated approach to care.
To incentivize employee participation in this novel arrangement, the employer offered significant financial benefits: co-pays for brand-name drugs were halved, and generic medications became entirely free. This direct financial incentive proved incredibly effective, leading to an astounding 90% buy-in among the company’s diabetic population. Such a high engagement rate is a critical indicator of program success, demonstrating that employees are willing to embrace new approaches when clear benefits and support are provided.
Bigler highlighted the philosophy behind this engagement-driven model. "We’re borne out of an engagement strategy," she affirmed. "How do we marry that with health coaching and pharmacy engagement? These are people that we want to live good lives and take really good care of these employees." This statement underscores a foundational belief that employee well-being is not just a cost center but a human investment, and that a holistic approach integrating financial incentives with personalized health support is paramount.
The partnership extended to Spire Wellness, a key provider of wellness services, which played a pivotal role in defining and tracking objectives. Kelly Fenol, managing director with Spire Wellness, emphasized the critical importance of baseline data. "One of the first things you have to do is have a baseline," Fenol explained. "If you don’t know where you’re starting, how are you ever going to get a delta? Where do we move financially and for the health of the population? What does that look like? What are the financials?" This rigorous, data-centric approach ensures that interventions are not only implemented but also continuously monitored and evaluated against clear key performance indicators (KPIs).
By meticulously defining objectives and implementing specific strategies to achieve them, the team was able to precisely measure success. "We can tell you, with this client, what percent of our folks with a diabetic condition are high risk, what percent are filling GLP-1, what’s our engagement percentage, cost per patient, all of those things that are really key performance indicators for success," Conner articulated. This granular level of data allows for ongoing optimization and demonstrates tangible value to the employer.
Broader Implications and a Paradigm Shift in Benefits Strategy
The success of this case study offers profound implications for the broader landscape of employer-sponsored healthcare and benefits management. It signifies a potential paradigm shift away from reactive, fragmented care models towards proactive, integrated, and data-driven health management.
- Re-evaluating PBM Relationships: The decision to exclude diabetic medications from the standard PBM and establish a specialty PBM suggests a growing trend among employers to exert greater control over high-cost drug categories. This model allows for more transparent pricing, direct negotiation, and the ability to link drug coverage to specific wellness and coaching programs, moving beyond the traditional PBM black box.
- The Power of Health Coaching and Engagement: The mandatory health coaching program, coupled with strong financial incentives, proved instrumental in achieving high engagement and improved health outcomes. This highlights the critical role of personalized support and behavioral change interventions alongside pharmaceutical treatments. It underscores that medication alone, especially for chronic conditions, is often insufficient without lifestyle modifications and ongoing guidance.
- Focus on Remission, Not Just Management: Shifting the goal from merely "managing" a chronic condition to actively working towards "remission" represents a more ambitious and ultimately more cost-effective approach. While not all chronic conditions are reversible, empowering individuals to achieve a state of remission through comprehensive support can significantly reduce long-term healthcare utilization and improve quality of life.
- Data-Driven Decision Making: The emphasis on establishing baselines, tracking KPIs, and measuring financial and health deltas is paramount. In an era of escalating costs, employers require concrete data to justify investments in benefits programs and to continuously refine their strategies. This approach transforms benefits from an overhead expense into a strategic investment with measurable returns.
- Ethical Considerations and Employee Well-being: While cost savings are a significant driver, the underlying motivation for such programs is often deeply rooted in a genuine desire to improve employee health and well-being. Healthier employees are not only more productive but also contribute to a more positive and sustainable workplace culture. The case study implicitly argues that a well-designed benefits strategy can achieve both financial prudence and enhanced employee welfare.
For the employer in question, these strategic maneuvers culminated in substantial financial relief, with a $1 million reduction in healthcare spending within the first year. Crucially, this was achieved while simultaneously elevating the overall health status of their employee population. "We also saw almost 60% of the population after just one year approaching diabetes remission," Bigler remarked, reinforcing the dual benefit. "These are people who are taking better care of themselves. They’re teaching their kids better habits as well." This ripple effect, extending beyond the individual employee to their families and communities, underscores the profound societal impact of well-conceived employer health initiatives.
The discourse at the BenefitsPRO Broker Expo, centered on GLP-1 drugs and innovative diabetes management, serves as a critical call to action for employers and benefits advisors. It highlights that while the cost of advanced medications like GLP-1s is undeniable, the true challenge lies not just in managing these costs, but in integrating them into a holistic strategy that prioritizes data-driven decision-making, proactive health management, and genuine employee engagement. The path forward demands creativity, collaboration, and a steadfast commitment to both fiscal responsibility and the enduring health of the workforce.
